$6.00
At close: Sep 18, 5:00 PM EST
OXFORD BIOMEDICA PLC NEW by Oxford Biomedica PLC Stock News
OXBDFOTCPK
Latest OXFORD BIOMEDICA PLC NEW by Oxford Biomedica PLC Stock News | OTC:OXBDF | Benzinga
Get the latest news on OXFORD BIOMEDICA PLC NEW by Oxford Biomedica PLC stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on OXFORD BIOMEDICA PLC NEW by Oxford Biomedica PLC performance
Categories: All
Wednesday, February 04, 2026
Friday, July 01, 2022
- The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
- Benzinga Before The Bell: Kohl's Deal Talks Cancellation, Tesla's Racial Discrimination Lawsuit, Nio's Strong June Deliveries And Other Top Financial Stories Friday, July 1
- Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca's COVID-19 Vaccine
Tuesday, February 01, 2022
Friday, January 28, 2022
Thursday, December 02, 2021
Wednesday, October 20, 2021
Wednesday, August 25, 2021
Friday, May 28, 2021
Wednesday, May 19, 2021
Tuesday, May 18, 2021
Wednesday, April 28, 2021
Thursday, March 25, 2021
Monday, February 15, 2021
Saturday, February 06, 2021
Thursday, February 04, 2021
Wednesday, February 03, 2021
- Oxford Vaccine Group Chief Pollard Says Autumn Is Timeline for Having New Vaccines Against Variants Available for Use
- Covid-19 Vaccine AstraZeneca Confirms its Covd-19 Vaccine Provides 100% Protection Against Severe Disease, Hospitalization and Death in Primary Analysis of Phase III Trials; Said Results Demonstrated Vaccine Efficacy of 76% After First Dose, With Protection Maintained to the Second Dose
Wednesday, January 27, 2021
Tuesday, January 26, 2021
Wednesday, January 06, 2021
Saturday, January 02, 2021
Friday, January 01, 2021
Saturday, December 26, 2020
Wednesday, December 09, 2020
Thursday, December 03, 2020
Wednesday, December 02, 2020
Thursday, November 26, 2020
Monday, November 23, 2020
- Director Of Jenner Institute Hill Tells Reute...PRO
- Oxford's Hill Says All UK Adults Could Have C...PRO
- Oxford's Hill Says We Will Likely Be Close To...PRO
- AstraZeneca COVID-19 Vaccine Shows Average Efficacy of 70%
- AstraZeneca's Pam Cheng Says Will have 200M COVID Vaccine Doses by Year-end; 700M by End of Q1 Gloablly
- Oxford Vaccine Group Director Pollard Says Optimistic About Immune Response Lasting at Least a Year
Thursday, November 19, 2020
- The Lancet Published Safety and Immunogenicity of Oxford-AstraZeneca Potential Covid-19 Vaccines; Said Vaccine Appears to be Better Tolerated in Older Adults than Younger Adults
- Oxford Vaccine Trial Chief Pollard Says the Vaccine is Extremely Well Tolerated by Those Over 55; Says Going to Be Before Christmas on Unblinding the Trial
Wednesday, November 04, 2020
- UK Vaccine Taskforce Head Bingham Says Slim Chance a Vaccine Will Wipe Out Coronavirus; Says Data is Pretty Good for a Vaccine Which Will Work to Some Degree
- UK Vaccine Taskforce Head Bingham Says Hope for Data in Early December on Oxford and Pfizer Vaccines
- Pollard Says There is a Small Chance of Vaccine Before Christmas
- Oxford Vaccine Trial Chief Pollard Said First Step of Finding Whether the Vaccine Works Could Happen This Year; Says Getting Closer to Trial Results, Not There Yet
